The series is stated in the current share scale after splits; dividends are not included in the price
AbbVie is a drug maker that has lived through the patent expiry of its flagship medicine and replaced it with a next generation.
For years the base was Humira, an autoimmune treatment and one of the best-selling drugs in the industry's history. Its patent expiry and the arrival of biosimilars tested the company's durability: revenue from that product declines, and the question was what would replace it.
The replacement is a next generation of medicines in the same field, plus neuroscience, oncology and aesthetics following the Allergan acquisition, including Botox. That diversification leaves the company less dependent on a single product than it historically was.
The industry model is unchanged: high margins under patent protection, a sharp fall once it ends, so value rests on the pipeline and on deals for external assets. AbbVie pays a dividend that is high by sector standards and is held for cash flow.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
AbbVie Inc. (ABBV) is a company in the Health care sector; its shares trade on NYSE.
The price of AbbVie Inc. (ABBV) on November 2, 2026 is 289.73 $, −1.75 % on the day. Over 52 weeks the stock traded between 190.75 $ and 291.33 $; the price now sits 98 % of the way up that range. Over the past year the price changed by +25.28 %. The P/E ratio is 85.63, which is above the sector median (24.61). Market capitalization is 540.35 billion $, rank 3 among 380 stocks of the same industry with a known capitalization.
AbbVie Inc. trades on NYSE under the ticker ABBV. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks ABBV has traded between 190.75 $ and 291.33 $. As of 2 November 2026 the price stood 92.12 % of the way from the 52-week low to the high.
Over one year ABBV shares rose 25.28 %; over six months they rose 35.60 %. Volatility over 90 days is 25.96 %. Dividends are not included: this is price change only, as of 2 November 2026.
ABBV trades at a price-to-earnings ratio of 85.6, above the sector median of 24.6. Price to sales is 8.4, above the sector median of 3.6. Calculated from reports for the period ending 30 June 2026.
AbbVie Inc. reported revenue of 64.4B $ and net income of 6.3B $ over the last four quarters. Net margin is 9.80 %. Revenue changed by +10.39 % year over year. Earnings per share are 3.54 $. Market capitalisation is 540.4B $.
